Efflux-Mediated Multidrug Tolerance in Replicating Mycobacteria

ResearchWorks/Manakin Repository

Search ResearchWorks


Advanced Search

Browse

My Account

Statistics

Related Information

Efflux-Mediated Multidrug Tolerance in Replicating Mycobacteria

Show simple item record

dc.contributor.advisor Ramakrishnan, Lalita en_US
dc.contributor.author Adams, Kristin Nicole en_US
dc.date.accessioned 2012-09-13T17:24:03Z
dc.date.available 2013-09-14T11:05:27Z
dc.date.issued 2012-09-13
dc.date.submitted 2012 en_US
dc.identifier.other Adams_washington_0250E_10066.pdf en_US
dc.identifier.uri http://hdl.handle.net/1773/20573
dc.description Thesis (Ph.D.)--University of Washington, 2012 en_US
dc.description.abstract A major roadblock in the global eradication of tuberculosis lies in the long duration of treatment required for cure. This well documented need for long-term therapy is historically attributed to the infecting mycobacteria becoming dormant within the host so that they are no longer killed by currently used antitubercular drugs that target actively growing bacteria. The dormancy model of tolerance has been the center of antitubercular drug research with the pursuit of drugs to target bacterial determinants that are expressed in the nonreplicating phase of infection. My PhD dissertation research determined that replicating bacteria become tolerant to multiple antitubercular agents upon macrophage residence through the induction of distinct efflux pumps that are also required for intracellular growth. My findings provide a mechanistic explanation for the clinical tuberculosis treatment data gathered over the last 50 years where the length of treatment required for cure correlates with bacterial burdens. Moreover, the addition of the calcium channel blocker, verapamil reverses this tolerance to the front-line drugs, isoniazid and rifampicin. If the tolerance mechanism revealed by my work is indeed a substantial contributor to the tolerance of active tuberculosis, then the addition of efflux pump inhibitors such as verapamil to the current antitubercular regimen should shorten the course of curative therapy. en_US
dc.format.mimetype application/pdf en_US
dc.language.iso en_US en_US
dc.subject Drug Tolerance; Efflux Pump; Mycobacteria; Tuberculosis en_US
dc.subject.other Microbiology en_US
dc.subject.other Microbiology en_US
dc.title Efflux-Mediated Multidrug Tolerance in Replicating Mycobacteria en_US
dc.type Thesis en_US
dc.embargo.terms Restrict to UW for 1 year -- then make Open Access en_US


Files in this item

Files Size Format View
Adams_washington_0250E_10066.pdf 2.258Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record